A. Kirkpatrick

3.5k total citations · 1 hit paper
39 papers, 2.6k citations indexed

About

A. Kirkpatrick is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, A. Kirkpatrick has authored 39 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 10 papers in Otorhinolaryngology. Recurrent topics in A. Kirkpatrick's work include Lung Cancer Research Studies (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Head and Neck Cancer Studies (10 papers). A. Kirkpatrick is often cited by papers focused on Lung Cancer Research Studies (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Head and Neck Cancer Studies (10 papers). A. Kirkpatrick collaborates with scholars based in Netherlands, Belgium and France. A. Kirkpatrick's co-authors include Tarek Sahmoud, J.-L. Lefebvre, Laurence Collette, B Luboïnski, Dominique Chevalier, Otilia Dalesio, Jaap Verweij, Giuseppe Giaccone, M. van Glabbeke and Pieter E. Postmus and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

A. Kirkpatrick

39 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial

1996 971 citations J.-L. Lefebvre, Dominique Chevalier et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Kirkpatrick Netherlands	22	1.4k	1.3k	1.2k	988	291	39	2.6k
Rafael Martínez‐Monge Spain	27	984 0.7×	926 0.7×	281 0.2×	919 0.9×	187 0.6×	128	2.3k
Deborah L. Driscoll United States	33	1.2k 0.9×	1.3k 1.0×	177 0.1×	871 0.9×	202 0.7×	59	2.5k
D. Chassagne France	23	518 0.4×	812 0.6×	485 0.4×	1.0k 1.0×	174 0.6×	85	2.5k
Renzo Corvò Italy	27	1.1k 0.8×	931 0.7×	1.1k 1.0×	978 1.0×	301 1.0×	179	2.8k
Pasquale Quattrone Italy	24	365 0.3×	1.2k 0.9×	1.1k 0.9×	1.7k 1.7×	282 1.0×	62	2.5k
S. Hoffstetter France	27	481 0.3×	591 0.4×	701 0.6×	920 0.9×	198 0.7×	83	1.9k
F. Eschwège France	30	1.4k 1.0×	1.4k 1.0×	1.3k 1.1×	2.1k 2.1×	198 0.7×	106	3.3k
William J. Spanos United States	29	810 0.6×	993 0.7×	1.0k 0.8×	1.0k 1.1×	208 0.7×	60	2.8k
Antoine Lusinchi France	23	859 0.6×	745 0.6×	1.1k 0.9×	1.2k 1.2×	199 0.7×	34	2.2k
Nicolas Daly‐Schveitzer France	20	535 0.4×	472 0.4×	476 0.4×	480 0.5×	169 0.6×	52	1.4k

Countries citing papers authored by A. Kirkpatrick

Since Specialization

Citations

This map shows the geographic impact of A. Kirkpatrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Kirkpatrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Kirkpatrick more than expected).

Fields of papers citing papers by A. Kirkpatrick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Kirkpatrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Kirkpatrick. The network helps show where A. Kirkpatrick may publish in the future.

Co-authorship network of co-authors of A. Kirkpatrick

This figure shows the co-authorship network connecting the top 25 collaborators of A. Kirkpatrick. A scholar is included among the top collaborators of A. Kirkpatrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Kirkpatrick. A. Kirkpatrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vainre, Maris, Tim Dalgleish, A. Kirkpatrick, et al.. (2022). Mindfulness training for work performance: A systematic review and meta-analysis of randomised controlled trials. PsyArXiv (OSF Preprints). 1 indexed citations

Keus, Ronald B., Remi A. Nout, Jean‐Yves Blay, et al.. (2013). Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998). Annals of Oncology. 24(10). 2672–2676. 105 indexed citations

Nooij, M., Jeremy Whelan, V. Bramwell, et al.. (2004). Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. European Journal of Cancer. 41(2). 225–230. 39 indexed citations

Gortzak, E., Alberto Azzarelli, J. Buesa, et al.. (2001). A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. European Journal of Cancer. 37(9). 1096–1103. 275 indexed citations

Splinter, Ted A.W., Paul E. Van Schil, G. Kramer, et al.. (2000). Randomized Trial of Surgery Versus Radiotherapy in Patients with Stage IIIA (N2) Non–Small-Cell Lung Cancer After a Response to Induction Chemotherapy: EORTC 08941. Clinical Lung Cancer. 2(1). 69–72. 21 indexed citations

Murdoch, John, et al.. (2000). The surgical management of cervical carcinoma within the South West of England: progress through an audit loop. BJOG An International Journal of Obstetrics & Gynaecology. 107(3). 308–315. 2 indexed citations

Voûte, P.A., R L Souhami, M. Nooij, et al.. (1999). A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. Annals of Oncology. 10(10). 1211–1218. 38 indexed citations

Dombernowsky, P, H.T. Mouridsen, D. Crowther, et al.. (1998). High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. British Journal of Cancer. 78(12). 1634–1639. 78 indexed citations

Verweij, Jaap, P.H.M. de Mulder, Alexander de Graeff, et al.. (1996). Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. Annals of Oncology. 7(8). 867–869. 47 indexed citations

10.

Postmus, Pieter E., Giorgio V. Scagliotti, Harry J.M. Groen, et al.. (1996). Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase iii trial. European Journal of Cancer. 32(9). 1498–1503. 24 indexed citations

11.

Lefebvre, J.-L., Dominique Chevalier, B Luboïnski, et al.. (1996). Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial. JNCI Journal of the National Cancer Institute. 88(13). 890–899. 971 indexed citations breakdown →

12.

Splinter, Ted A.W., Tarek Sahmoud, Jan Festen, et al.. (1996). Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology. 14(1). 127–134. 19 indexed citations

13.

Postmus, Pieter E., Egbert F. Smit, Hanny Haaxma-Reiche, et al.. (1995). Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology. 13(3). 660–665. 50 indexed citations

14.

Clavel, M., Jan B. Vermorken, F. Cognetti, et al.. (1994). Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 5(6). 521–526. 210 indexed citations

15.

Vermorken, J. B., Jaco J. Verweij, F. Cognetti, et al.. (1993). Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group. Annals of Oncology. 4(9). 785–788. 69 indexed citations

16.

Giaccone, Giuseppe, Otilia Dalesio, Gordon McVie, et al.. (1993). Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology. 11(7). 1230–1240. 108 indexed citations

17.

Mattson, K., Giuseppe Giaccone, A. Kirkpatrick, et al.. (1992). Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology. 10(5). 824–828. 48 indexed citations

18.

Planting, A.S.T., Andrea Ardizzoni, Giuseppe Giaccone, et al.. (1991). Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872. Cancer Chemotherapy and Pharmacology. 28(2). 145–146. 5 indexed citations

19.

Postmus, PE, et al.. (1989). High dose etoposide for brain metastases of small cell lung cancer. A phase II study. British Journal of Cancer. 59(2). 254–256. 34 indexed citations

20.

Postmus, Pieter E., A. Kirkpatrick, Otilia Dalesio, et al.. (1988). Two carboplatin-containing regimens for small cell lung cancer: preliminary results of a randomized phase II trial. Cancer Treatment Reviews. 15. 41–44. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact